Suppr超能文献

减重手术后静脉血栓栓塞症预防的延长出院后预防。

Extended Post Discharge Prophylaxis for Venous Thromboembolism Prevention After Bariatric Surgery.

机构信息

Division of Metabolic and Bariatric Surgery, Columbia University Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, Herbert Irving Pavilion, 161 Fort Washington Ave, Rm 562, New York, NY, 10032, USA.

出版信息

Obes Surg. 2024 Apr;34(4):1217-1223. doi: 10.1007/s11695-024-07100-z. Epub 2024 Feb 27.

Abstract

PURPOSE

The utility of routine post-discharge VTE prophylaxis after bariatric surgery remains a matter of debate. While inpatient chemical prophylaxis decreases the risk of fatal pulmonary embolism, most thromboembolic events occur after discharge and carry high morbidity and mortality. To address this risk, apixaban was introduced as extended prophylaxis for 30 days after surgery.

MATERIALS AND METHODS

The study ranges between 1/2014 and 7/2022. Apixaban was incorporated as routine extended prophylaxis protocol in 05/2017 and is dosed at 2.5 mg BID for 30 days. There were two study groups: those who received apixaban on discharge (n = 1443; 60%) and those who did not (n = 953; 40%). Patients with concern for postoperative bleeding (hypotension, unexplained tachycardia with hematocrit drop > 6%, hematocrit drop > 9%), or on preoperative anticoagulant/antiplatelet therapy (except aspirin), were not discharged on apixaban. Post-discharge VTE, readmission, transfusion, and reoperation rates were compared between groups.

RESULTS

There were 2396 consecutive primary bariatric operations: sleeve gastrectomy (1949; 81%), Roux-en-Y gastric bypass (419; 18%), and duodenal switch (28; 1%). There were no post-discharge VTEs in patients treated with apixaban vs. five (0.5%) VTEs in patients who did not receive treatment; p = 0.02. There was a higher incidence in post-discharge bleeding events in the apixaban group (0.5 vs 0.3%; p = 0.75), mostly requiring readmission for monitoring without intervention or transfusion. In the apixaban group, one patient underwent EGD for bleeding while another required blood transfusion; there were no reoperations for bleeding.

CONCLUSION

There were no post-discharge VTEs in patients who received apixaban. Treatment was associated with a higher risk of self-resolving bleeding events. This study adds to the increasing body of evidence supporting the benefit of routine, extended oral chemoprophylaxis after bariatric surgery.

摘要

目的

减重手术后常规出院后静脉血栓栓塞症(VTE)预防的效用仍存在争议。虽然住院期间的化学预防可降低致命性肺栓塞的风险,但大多数血栓栓塞事件发生在出院后,且具有较高的发病率和死亡率。为了应对这一风险,阿哌沙班被引入作为手术后 30 天的扩展预防措施。

材料和方法

本研究的时间范围为 2014 年 1 月至 2022 年 7 月。阿哌沙班于 2017 年 5 月被纳入常规扩展预防方案,剂量为每天 2.5 毫克,每日两次,共 30 天。有两个研究组:一组在出院时接受阿哌沙班(n=1443;60%),另一组未接受(n=953;40%)。对于术后出血(低血压、原因不明的心动过速伴血细胞比容下降>6%、血细胞比容下降>9%)或术前接受抗凝/抗血小板治疗(除阿司匹林外)的患者,不给予阿哌沙班出院。比较两组之间的出院后 VTE、再入院、输血和再次手术的发生率。

结果

共进行了 2396 例原发性减重手术:袖状胃切除术(1949 例;81%)、胃旁路术(419 例;18%)和十二指肠转位术(28 例;1%)。接受阿哌沙班治疗的患者中无出院后 VTE,而未接受治疗的患者中有 5 例(0.5%)VTE;p=0.02。阿哌沙班组的出院后出血事件发生率较高(0.5%比 0.3%;p=0.75),大多需要入院监测而无需干预或输血。在阿哌沙班组中,一名患者因出血而行 EGD,另一名患者需要输血;无因出血而再次手术。

结论

接受阿哌沙班治疗的患者无出院后 VTE。治疗与自行缓解的出血事件风险增加相关。本研究增加了越来越多的证据,支持减重手术后常规进行延长口服化学预防的益处。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验